Atlas Trials

Immunotherapy for High Risk/Relapsed CD19+ Acute Lymphoblastic Leukaemia, B-cell Non-Hodgkin's Lymphoma (B-NHL) and Chronic Lymphocytic Leukaemia (CLL)/ Small Lymphocytic Lymphoma (SLL) Using CAR T-cells to Target CD19

Clinical trial NCT02935257 · ACTIVE_NOT_RECRUITING

Trial details

NCT number
NCT02935257
Sponsor
University College, London
Status
ACTIVE_NOT_RECRUITING
Phase
Phase 1
Study type
INTERVENTIONAL
Leukemia, Lymphoblastic, Acute, Lymphoma
Start date
2017-09-29
Primary completion
2024-08-15
Enrollment
72

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.